Company intelligence / Profile preview

Actus Therapeutics

Chapel Hill, North Carolina, United Statesotc.duke.edu ↗

Ownership: Private
Development stage: Phase 1

Overview

Actus Therapeutics was founded in 2017 as a portfolio company under Asklepios BioPharmaceutical, Inc. Its primary goal was to develop targeted low-dose AAV-based gene therapies for rare diseases such as Pompe disease using technology licensed from Duke University. The lead program focused on addressing the underlying enzyme deficiency in Pompe through gene transfer. There are no publicly available results indicating successful completion of advanced clinical trials or commercialization; the most recent activity involved recruiting patients for early-stage studies around its founding period.[1][2][4]

Therapeutic areas: Rare DiseasesNeurology
Modalities: Gene therapy (AAV vectors)
Industry: Biotech

Drug pipeline

1 asset

ACTUS-101

Phase 1/2

Indications: Pompe disease

Partnerships

Technology licensing/collaboration with Duke University/Dwight Koeberl’s laboratory

Beyond the preview

Go deeper on Actus Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Actus Therapeutics.

Explore the full profile